The miRNA market has crossed a strategic threshold. The question is no longer whether adoption in clinical diagnostics and precision medicine will accelerate—it’s whether your organization has the intelligence infrastructure to act on that acceleration before competitors do. The Structural Shift in Molecular Diagnostics Market disruptions in biotechnology often follow a pattern:...